Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Open-label, Multi-centre Phase II Study of BAY43-9006 (Sorafenib) Versus Standard Treatment With Interferon Alpha-2a in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma.

NCT00117637 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT00117637
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00117637 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Open-label, Multi-centre Phase II Study of BAY43-9006 (Sorafenib) Versus Standard Treatment With Interferon Alpha-2a in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma.
Lead sponsor
Bayer
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2005
Completion date
March 31, 2009
Enrollment
189 (actual)
Sites
42

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, renal cell